SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic ...
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
SAN DIEGO - Skye Bioscience, Inc. (NASDAQ:SKYE), a clinical-stage biopharmaceutical company, has announced key changes to its Board of Directors and the upcoming launch of a Phase 2 clinical trial for ...
Skye Bioscience (SKYE) announced the Board has appointed independent director Paul Grayson as Skye’s new Chairman of the Board, effective October 25, 2024. Grayson currently serves as a member of Skye ...
Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results